Gilead Sciences
Researchers Showcase New Scores, Biomarkers, Signatures for Predicting CAR T-Cell Outcomes at ASH
Premium
Across three studies, researchers demonstrated how various biomarkers can inform trial design and predict lymphoma patients' outcomes on CAR T-cell therapy.
DiaSorin Q3 Non-COVID-19 Revenues Rise 2 Percent, Collaborates With Gilead Sciences on HDV Assay
The firm reported its immunodiagnostics revenues rose on strong sales in Europe and North America while molecular instrument sales normalized from previous highs.
Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery
Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
Biocartis, Kite Sign Development Agreement for Immunotherapy Assays
The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.